Maxims of Tech: Rules of Engagement for a Fast Changing Environment

Gene therapy 1.0 is a flop, but biotech isn't worried - STAT

 
 
STATGene therapy 1.0 is a flop, but biotech isn't worriedSTAThe Western world's first gene therapy is soon to become but a footnote in biotech history, doomed by minuscule demand and a colossal price. But its failure has hardly dampened the enthusiasm of the scientists and biotech companies betting that gene ...
 
Related NewsFeeds

Corbus Pharmaceuticals Can Hit New Highs By Year's EndSeeking AlphaCorbus Pharmaceuticals (NASDAQ:CRBP) has made waves recently for its cystic fibrosis (CF) Phase II data for Anabasum, but it is t

1 visits

BRIEF-China Regenerative Medicine International says during period between 30 May & 6 June, co received notices ...ReutersReuters is the news and media division of Thomson Reuters. Thomson Reuters is

1 visits

EurekAlert (press release)Bioengineers create more durable, versatile wearable for diabetes monitoringEurekAlert (press release)IMAGE: Researchers at the University of Texas at Dallas have developed a

1 visits

Medical News TodayType 1 diabetes: Almost half of patients produce insulinMedical News TodayResearchers from Uppsala University in Sweden found that nearly half of patients who had been living with di

1 visits

MedscapeCALMing Insights That Make a SONIC BoomMedscapeWhen it comes to clinical endpoints, we have recognized for several years that symptoms do not correlate well with endoscopic or other "biologic"

1 visits

RescueDiabetes is manageable-unless you live in SyriaRescueDiabetes can be managed. It's a chronic disease, marked by the body's inability to either produce or effectively use insulin to contr

1 visits

Madison.comBetter Know a Marijuana Stock: Arena PharmaceuticalsMadison.comUnlike GW Pharmaceuticals and Zynerba Pharmaceuticals, which rely on cannabinoid-based medicines to fill out the entirety of t

0 visits

IBD News TodayTreatment Options: Biologic Medication Entyvio Is Next for MeIBD News TodayIn a single article outside of my usual pattern of writing a series, I wanted to focus more on the biologic dru

1 visits

MedscapeOral Insulin May Delay Type 1 Diabetes Onset in 'Responders'MedscapeSAN DIEGO - Close relatives of people with type 1 diabetes who had certain autoantibodies believed to put them at hi

1 visits

Investorplace.comFriday's Vital Data: Advanced Micro Devices, Inc. (AMD), Valeant Pharmaceuticals Intl Inc (VRX) and BlackBerry Ltd ...Investorplace.comDespite a string of setbacks this week, the

1 visits

Channel NewsAsiaEU regulators greenlight US biotech Aveo's kidney cancer drugReutersEuropean regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney ca

1 visits

Eton Pharmaceuticals Names Sean Brynjelsen Chief Executive ...PR Newswire (press release)CHICAGO, June 23, 2017 /PRNewswire/ -- Eton Pharmaceuticals, Inc., a development stage pharmaceutical company,

0 visits

Motley Fool3 Biotech Stocks for Enterprising InvestorsMotley FoolBiotech stocks are a natural area of exploration for aggressive investors with high expectations for their stocks. After all, this high

0 visits

AVEO Oncology (AVEO) Announces Positive CHMP Opinion for Tivozanib as Treatment of Advanced Renal Cell ...StreetInsider.com... growth factor (VEGF) inhibitors are the standard of care treatment for ad

0 visits

Diabetes moving from affliction of affluent countries to a global problemMedical XpressThe number of people with diabetes has quadrupled from 1980 to 2014, and 415 million adults in the world now have

0 visits

BioPharma-Reporter.comEMA committee gives Samsung Bioepis nod for Humira biosimilar ImraldiBioPharma-Reporter.comThe EMA has recommended the approval of Samsung Bioepis' adalimumab biosimilar, pla

1 visits

Pfizer gets CRL on Epogen biosimilar from FDAPharmaceutical Business ReviewThe United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Pfizer in connection with

0 visits

Pharmaceutical Business ReviewNovartis' heart drug canakinumab meets primary endpoint in phase III studyPharmaceutical Business ReviewNovartis' heart drug ACZ885 (canakinumab) has met primary

1 visits

TechnoratiDiabetes Devices Market Is Predicted To Hit USD 28.2 Bn By 2022, Credence ResearchTechnoratiAccording to the latest report published by Credence Research, Inc. "Diabetes Devices Market Growt

1 visits

Biologic Response Modifiers Market Future Demand and Growth ...Medgadget (blog)Report Monitor Present's United States Biologic Response Modifiers Market 2017 Industry Trend Enhances The Decision M

0 visits

 
Maxims of Tech: Rules of Engagement for a Fast Changing Environment